SDEE member Crinetics Pharmaceuticals  was awarded a $2.7MM fast-track Phase I SBIR grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) to develop somatostatin receptor agonist drugs targeting chronic pain.